Bacterial Skin Infection

• EMA approval · 2026-01-20
  EMA Authorised: Daptomycin Hospira (daptomycin) — Pfizer Europe MA EEIG

  The EMA authorised Daptomycin Hospira (daptomycin) for marketing in the EU for soft tissue infections and bacterial skin infections, with de…

• FDA approval · 2025-11-10
  FDA Approved: CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE — Original Application (Cosette Pharmaceuticals, Inc.)

  FDA approved a generic topical product containing ciprofloxacin hydrochloride and hydrocortisone under an original application for Cosette P…

• FDA approval · 2025-05-13
  FDA Approved: MUPIROCIN — Original Application (Encube Ethicals, Inc.)

  FDA approves Encube Ethicals, Inc.'s original application for mupirocin topical antibiotic (generic mupirocin).

• EMA approval · 2024-11-20
  EMA Authorised: Tenkasi (previously Orbactiv) (oritavancin (diphosphate)) — Menarini International Operations Luxembourg S.A.

  The European Medicines Agency has authorised Tenkasi (oritavancin diphosphate) by Menarini International Operations Luxembourg S.A. for soft…

• FDA approval · 2024-07-08
  FDA Approved: MUPIROCIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

  FDA approved a supplemental application for Mupirocin by Glenmark Pharmaceuticals Inc., USA.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2021-08-04
  FDA Approved: MUPIROCIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

  FDA approved Glenmark Pharmaceuticals Inc., USA's supplemental application for mupirocin.